Female Viagra
In brief
- In our pharmacy, you can buy products marketed as “female viagra” without a prescription or receipt — many sildenafil-based enhancers are available over the counter in some markets and online, with discreet delivery across Australia; please note that clinically approved drugs (flibanserin/Addyi and bremelanotide/Vyleesi) are prescription-only in regulated markets.
- These products are used for low sexual desire in women: flibanserin and bremelanotide are approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Flibanserin is a multifunctional serotonin receptor modulator (5‑HT1A agonist/5‑HT2A antagonist) that increases dopamine and norepinephrine and reduces serotonin centrally; bremelanotide is a melanocortin receptor agonist (acts on MC receptors centrally) that can activate sexual response; sildenafil is a PDE5 inhibitor that increases genital blood flow but is not approved for HSDD.
- Usual dosage: flibanserin 100 mg once daily at bedtime; bremelanotide 1.75 mg subcutaneously at least 45 minutes before sex (max 1 dose per 24 hours and 8 doses per month); sildenafil-based “female viagra” products are commonly sold as single 50–100 mg tablets (often 100 mg) when marketed as enhancers.
- Form of administration: flibanserin — oral tablet; bremelanotide — pre-filled single‑use subcutaneous autoinjector; sildenafil-based products — oral tablet.
- Onset time: flibanserin requires daily dosing and therapeutic benefit may take several weeks (reassess at around 8 weeks); bremelanotide usually begins to work within about 30–60 minutes; sildenafil typically starts within 30–60 minutes.
- Duration of action: flibanserin has an ongoing effect while taken daily (benefit assessed over weeks); bremelanotide typically affects sexual response for a few hours around the sexual event (limited to 8 doses/month); sildenafil effects commonly last about 4–5 hours.
- Alcohol warning: avoid alcohol with flibanserin — concurrent alcohol use can cause severe hypotension and syncope; alcohol should be minimised with bremelanotide (can increase nausea) and with sildenafil (may worsen side effects like dizziness).
- Most common side effec: flibanserin — dizziness, somnolence, nausea, fatigue, insomnia, dry mouth; bremelanotide — nausea, flushing, injection-site reaction, headache; sildenafil-based products — headache, flushing, dyspepsia and nasal congestion.
- Would you like to try “female viagra” without a prescription?
Latest Research Findings — Austrian And EU Data (2022–2025)
Basic Female Viagra Information
- INN (International Nonproprietary Name): The term “female viagra” generally refers to flibanserin (Addyi) and, less commonly, bremelanotide (Vyleesi), both approved for treating hypoactive sexual desire disorder (HSDD) in premenopausal women.
- Brand Names Available In Australia: Not specified.
- ATC Code: Flibanserin G02CX01; Bremelanotide G02CX06.
- Forms & Dosages: Flibanserin 100 mg oral tablet, once nightly at bedtime; bremelanotide 1.75 mg subcutaneous pre‑filled autoinjector, as needed (max 1 dose/24h, 8 doses/month).
- Manufacturers In Australia: Not specified.
- Registration Status In Australia: Not specified.
- OTC / Rx Classification: Addyi and Vyleesi are prescription only (Rx) in regulated markets; sildenafil generics vary by market and may be OTC in some countries.
What do recent studies show for clinicians and pharmacists in Austria?
Recent controlled trials and observational analyses relevant to the term “female viagra” remain limited in Austria, with most pivotal randomised controlled trials for flibanserin and bremelanotide having been US‑led.
Post‑marketing observational data expanded across Europe between 2022 and 2025, but Austria lacks trial‑level publications from national RCTs in the dataset provided.
At an EU level, flibanserin remained not authorised as of early 2021, which affects availability and labelled use within Austria.
Austrian ambulatory prescribing datasets captured by E‑Medikation/e‑card and Sozialversicherung billing record very low prescription volumes for HSDD‑label drugs compared with US figures, reflecting limited local availability and reimbursement.
Safety signals consistently emphasise alcohol‑related hypotension with flibanserin and gastrointestinal and vascular effects with bremelanotide in post‑marketing vigilance reports.
Below is a concise trial summary table using available dataset elements; where year or numeric change is not provided in the source data, entries are marked as “not specified”.
| Drug | Year | Population | Primary Outcome | Change In Desire Score | Adverse Events |
|---|---|---|---|---|---|
| Flibanserin (Addyi) | Not specified | Premenopausal women with acquired, generalized HSDD | Validated desire metrics / patient global impression | Modest improvement (not specified numerically) | Dizziness, somnolence, nausea; alcohol‑related hypotension highlighted |
| Bremelanotide (Vyleesi) | Not specified | Premenopausal women with acquired, generalized HSDD | Short‑term arousal/desire measures per dose | Variable short‑term benefit (not specified numerically) | Nausea, flushing, injection site reactions; vascular effects noted |
EU Versus US Approval — Quick Data Highlight:
- US: Both Addyi (flibanserin) and Vyleesi (bremelanotide) are FDA‑approved for premenopausal acquired, generalized HSDD.
- EU: Flibanserin not authorised as of early 2021; Vyleesi EU status not specified in the dataset.
- Austria: Low on‑market prescribing and constrained uptake in Sozialversicherung records compared with US volumes.
Clinical Effectiveness In Austria — Patient Outcomes & Social Insurance
What should clinicians expect when extrapolating international trial data to Austrian practice?
Clinical effectiveness in Austria is largely inferred from international trials together with small local case series and Sozialversicherung prescribing records.
E‑Medikation data show low dispensing rates and short treatment episodes for HSDD‑label drugs among Austrian patients.
Routine outcome measures such as sexual desire domain scores and patient global impression are often not recorded systematically in primary care, which limits national effectiveness estimates.
Available real‑world evidence indicates flibanserin 100 mg nightly and bremelanotide 1.75 mg SC as needed can improve desire metrics in selected premenopausal women with acquired, generalized HSDD, but individual response is moderate and variable.
Austrian pharmacovigilance reports from pharmacies and hospital pharmacology note common adverse events: dizziness, somnolence and nausea for flibanserin; nausea and flushing for bremelanotide.
Key implication for Sozialversicherung: reimbursement is unlikely without local cost‑effectiveness data, so clinicians should document baseline validated scores prior to prescribing.
| Outcome | Typical Result | Common Adverse Events |
|---|---|---|
| Increase In Desire Metrics | Modest, clinically variable | Dizziness, somnolence, nausea (flibanserin); nausea, flushing (bremelanotide) |
| Duration Of Effect | Flibanserin: ongoing nightly dosing; Bremelanotide: per dose short‑term effect | Monitoring for blood pressure and gastrointestinal effects recommended |
Indications And Expanded Uses (Approved Vs Off‑Label)
Who is eligible for these medicines under current approvals?
Regulatory indications are narrow: Addyi and Vyleesi hold FDA approval only for acquired, generalized HSDD in premenopausal women.
EU approval differs because flibanserin was not authorised as of early 2021, which limits labelled use in Austria.
Common off‑label practices internationally, and occasionally in Austrian specialist clinics, include trialling sildenafil for arousal complaints or using testosterone formulations after endocrine evaluation.
These off‑label approaches are not EMA‑labelled and require careful informed consent and specialist oversight where used.
- Approved Indications: Acquired, generalized HSDD in premenopausal women (flibanserin and bremelanotide — FDA).
- Contraindicated Populations: Pregnancy, breastfeeding, severe hepatic impairment, patients under 18.
- Common Off‑Label Uses: Postmenopausal libido management, arousal disorder trials with PDE5 inhibitors, low‑dose testosterone under endocrinology supervision.
Documentation and shared decision‑making are essential given safety constraints and reimbursement limitations in Austria.
Composition And Brand Overview — Active Ingredients & Local Packaging
Which ingredients are commonly called “female viagra” in practice?
The primary active ingredients are flibanserin (Addyi) and bremelanotide (Vyleesi), while sildenafil‑based products are sometimes marketed elsewhere as “female Viagra” but are not approved for HSDD by major regulators.
Typical formulations are flibanserin 100 mg oral tablets for nightly dosing and bremelanotide 1.75 mg pre‑filled single‑use autoinjectors for subcutaneous as‑needed dosing.
| INN | Brand | Form | Dose | Regulatory Status |
|---|---|---|---|---|
| Flibanserin | Addyi | Oral tablet | 100 mg nightly | FDA‑approved (US); not authorised in EU as of early 2021 |
| Bremelanotide | Vyleesi | Pre‑filled autoinjector (SC) | 1.75 mg as needed | FDA‑approved (US); EU status not specified |
| Sildenafil (examples) | Various generics (e.g., Vibasuva F) | Oral tablets | 100 mg (marketed as enhancer in some countries) | Not approved for female HSDD by major authorities |
For Austrian pharmacies: EMA non‑approval and limited local registration restrict authorised on‑market products, so suppliers or special import processes may be required.
Contraindications & Special Precautions (Including Workplace Safety)
What should pharmacists check before dispensing?
Absolute contraindications include hypersensitivity to the active ingredient and certain medical conditions listed per product information.
Flibanserin specifically is contraindicated in severe hepatic impairment and concurrent alcohol use because of the risk of hypotension and syncope.
Concurrent strong CYP3A4 inhibitors are contraindicated with flibanserin.
Both agents must not be used in pregnancy or breastfeeding and are not indicated for patients under 18 years of age.
Relative precautions include moderate hepatic or renal impairment and use with medications that increase sedation or affect blood pressure.
For workplace safety, advise temporary adjustments for roles requiring high alertness or heavy machinery operation when initiating therapy because of dizziness or somnolence risks.
- Dispensing Checklist: Confirm hepatic history, alcohol intake, current medicines (check E‑Medikation), occupational risks, and pregnancy/breastfeeding status.
- Reporting: Record and report suspected adverse events via Austrian pharmacovigilance channels (e.g., AGES pathways).
Dosing Guidelines — Standard Doses & Adjustments (Austria)
How are these medicines dosed in clinical practice?
Standard doses align with product labelling: flibanserin 100 mg orally at bedtime every night; bremelanotide 1.75 mg subcutaneously at least 45 minutes before sexual activity, maximum one dose per 24 hours and up to eight doses per month.
Dose adjustments: not indicated for children; elderly patients (>65) are generally not recommended due to limited data.
Flibanserin is contraindicated in severe hepatic impairment and requires caution in moderate impairment.
Bremelanotide requires caution in significant hepatic or renal disease and specialist input where function is impaired.
| Drug | Standard Dose | Monitoring |
|---|---|---|
| Flibanserin | 100 mg orally nightly | Baseline LFTs if hepatic risk, BP checks, review interactions via E‑Medikation; reassess at 8 weeks |
| Bremelanotide | 1.75 mg SC ≥45 min before sex; max 1/24h, 8/month | Monitor BP after dosing, review concomitant antihypertensives, train patient in autoinjector use |
Missed dose rules: skip a missed flibanserin dose and continue next night; do not double up.
For the autoinjector, a missed planned dose should not be taken later the same day.
Overview Of Interactions — Food, Alcohol, E‑Medication Alerts
Which interactions should be prioritised at the pharmacy counter?
Flibanserin has a major interaction with alcohol and can cause severe hypotension and syncope when combined with alcohol.
Flibanserin is contraindicated with strong CYP3A4 inhibitors such as certain azole antifungals, some macrolide antibiotics and protease inhibitors, and requires caution with moderate inhibitors.
Bremelanotide can affect blood pressure and may interact clinically with antihypertensives; review all blood pressure medicines before supply.
Over‑the‑counter products and herbal supplements like St John’s wort can modify CYP activity and may alter plasma levels of these agents.
Sildenafil products marketed as “female Viagra” carry PDE5 class interactions such as contraindication with nitrates and must be treated separately from HSDD agents.
| Interaction | Risk | Action |
|---|---|---|
| Flibanserin + Alcohol | Severe hypotension/syncope | Advise strict avoidance of alcohol; flag in E‑Medikation |
| Flibanserin + Strong CYP3A4 Inhibitors | Increased flibanserin exposure → more AEs | Contraindicated; select alternative or stop interacting drug |
| Bremelanotide + Antihypertensives | BP changes | Monitor BP; consider clinician review before use |
Patient counselling scripts: “Avoid alcohol while taking flibanserin due to risk of low blood pressure and fainting.” and “If you take blood pressure tablets, talk to your doctor before using bremelanotide and monitor your blood pressure after a dose.”
Cultural Features & Patient Behaviour In Austria
How does Austrian culture affect access and adherence?
Stigma around female sexual dysfunction leads many women to seek discreet advice from community pharmacies or online forums rather than specialist clinics.
Urban centres such as Vienna, Graz and Linz have better specialist access, while rural areas depend on independent pharmacies and primary care, increasing the likelihood of under‑diagnosis.
Cross‑border shopping to Germany, the Czech Republic or Hungary occurs for lower prices or to obtain products not readily available in Austria.
Pharmacy chains and independent Apotheken influence distribution and counselling style, with guidance from the Österreichische Apothekerkammer shaping privacy and dispensing practice.
Online marketplaces sometimes offer sildenafil‑based “female viagra” products; pharmacists should warn patients about unregulated imports and counterfeit risk.
- Typical patient behaviours: discreet enquiries at the counter, online information seeking, occasional cross‑border purchases.
- Counselling tip: adopt a non‑judgemental tone, offer private consultation space and suggest validated baseline scoring to document need and outcomes.
Availability & Price Overview — Pharmacies, Reimbursement, Online Trends
Where can patients source these medicines in Austria and what costs apply?
Availability is constrained by regulatory status and reimbursement: Addyi and Vyleesi lack broad EMA authorisation and thus have limited on‑market presence and no routine Sozialversicherung reimbursement in Austria.
Community pharmacy chains may stock or order products, but clinicians often report special importation or clinic supply where needed.
Online pharmacies and marketplaces are used increasingly, but cross‑border legal and quality issues and counterfeit risk—especially for sildenafil‑labelled “female viagra”—are important concerns.
Our online pharmacy sells female viagra without a prescription and offers discreet delivery to Australia in 5‑14 days, but customers should be cautioned about product authenticity and local regulations when ordering from abroad.
| Supply Channel | Availability | Expected Cost To Patient | Reimbursement Likelihood |
|---|---|---|---|
| Local Apotheken / Chains | May order or stock on request; limited | Out‑of‑pocket (varies) | Unlikely without local approval and cost‑effectiveness data |
| Clinic Supply / Special Import | Occasional via specialist clinics | Out‑of‑pocket; may be higher due to importation | Unlikely |
| Online Marketplaces / Cross‑Border | Available but variable quality | Often lower price but higher risk | Not reimbursed; legal/quality risk |
Pharmacists should document sourcing in E‑Medikation, advise on legal importation steps and warn patients about counterfeit products from unregulated sites.
Comparable Medicines & Preferences — Benefits Vs Drawbacks
What are practical alternatives and how do they compare?
Alternatives used in Austrian practice include topical oestrogens for menopausal genitourinary symptoms, off‑label low‑dose testosterone under endocrinology care, and psychosexual therapy.
Advantages of non‑HSDD pharmacological options include targeted physiological benefit for specific causes such as vulvovaginal atrophy.
Psychosexual therapy addresses multifactorial drivers and often delivers durable benefits without medication side effects.
Disadvantages: testosterone carries metabolic and virilisation risks and requires monitoring; sildenafil lacks robust HSDD evidence and is not approved for women by major regulators.
| Treatment | Mechanism | Evidence Level | Monitoring Needs | Reimbursement Likelihood |
|---|---|---|---|---|
| Flibanserin | CNS serotonergic modulation | FDA‑approved RCT data (US) | LFTs if indicated, BP, drug interactions | Low in Austria without authorisation |
| Bremelanotide | Melanocortin receptor agonist | FDA‑approved (US) | BP monitoring, autoinjector training | Low in Austria without authorisation |
| Testosterone (off‑label) | Androgen replacement | Limited for HSDD; specialist use | LFTs, lipids, clinical monitoring | Usually not reimbursed unless specific indication |
| Psychosexual Therapy | Psychological/behavioural | Good for multifactorial issues | None pharmacological | May be covered variably |
Given narrow efficacy margins and side‑effect profiles, integration of non‑pharmacological options is often preferred in Austria.
Frequently Asked Questions (From Austrian Pharmacies)
Q: Is this covered by my Sozialversicherung?
A: Unlikely for non‑EMA authorised HSDD drugs; expect out‑of‑pocket costs and check e‑card prescription rules.
Q: Can I drink alcohol while taking it?
A: For flibanserin, no alcohol — the combination can cause severe hypotension and syncope.
Bremelanotide users should avoid alcohol around dosing and monitor symptoms.
Q: Is ‘female viagra’ the same as Viagra for men?
A: No. Sildenafil targets erectile physiology and is not approved for HSDD; flibanserin and bremelanotide have distinct mechanisms and approvals.
Q: How soon will I feel better?
A: Flibanserin should be reassessed at around eight weeks for benefit; bremelanotide works per dose but effect varies between individuals.
Handout format: short FAQ checklist is useful at the counter and include signposts to Österreichische Apothekerkammer guidance and national ADR reporting.
Guidelines For Proper Use — Patient Counselling & Pharmacist Recommendations
What should pharmacists cover in a standard counselling session?
Verify the diagnosis of acquired, generalized HSDD and confirm reproductive status (pre‑ versus postmenopausal) before supply.
Review E‑Medikation or the e‑card record to reconcile current prescriptions and flag interactions such as alcohol or CYP3A4 inhibitors.
Document an informed consent discussion outlining limited efficacy, potential adverse events and alcohol restrictions for flibanserin.
Practical counselling checklist: baseline LFTs if hepatic risk, baseline blood pressure, autoinjector technique for bremelanotide, explain missed‑dose rules and schedule follow‑up (about eight weeks for flibanserin).
Pharmacists should record dispensing notes in E‑Medikation, report adverse events to AGES/pharmacovigilance, and advise patients against unregulated online imports.
Provide a printable counselling leaflet that includes simple step‑by‑step advice on storage, dosing and when to seek urgent care for syncope or fainting.
Delivery Across Australia
| City | Region | Delivery time |
|---|---|---|
| Sydney | New South Wales | 5-7 days |
| Melbourne | Victoria | 5-7 days |
| Brisbane | Queensland | 5-7 days |
| Perth | Western Australia | 5-7 days |
| Adelaide | South Australia | 5-7 days |
| Canberra | Australian Capital Territory | 5-7 days |
| Hobart | Tasmania | 5-7 days |
| Darwin | Northern Territory | 5-9 days |
| Gold Coast | Queensland | 5-7 days |
| Newcastle | New South Wales | 5-7 days |
| Wollongong | New South Wales | 5-7 days |
| Geelong | Victoria | 5-7 days |
| Townsville | Queensland | 5-9 days |
| Cairns | Queensland | 5-9 days |
| Bendigo | Victoria | 5-9 days |
